Formins stimulate actin filament assembly for fundamental cellular processes including division, adhesion, establishing polarity, and motility. A formin inhibitor would be useful because most cells express multiple formins whose functions are not known and because metastatic tumor formation depends on the deregulation of formin-dependent processes. We identified a general small molecule inhibitor of formin homology 2 domains (SMIFH2) by screening compounds for the ability to prevent formin-mediated actin assembly in vitro. SMIFH2 targets formins from evolutionarily diverse organisms including yeast, nematode worm, and mice, with a half-maximal inhibitor concentration of 5 to 15 mM. SMIFH2 prevents both formin nucleation and processive barbed end elongation and decreases formin's affinity for the barbed end. Furthermore, low micromolar concentrations of SMIFH2 disrupt formin-dependent, but not Arp2/3 complex-dependent, actin cytoskeletal structures in fission yeast and mammalian NIH 3T3 fibroblasts.
INTRODUCTION
Cells assemble diverse actin-dependent structures for a variety of fundamental processes, each of which is thought to be reliant on specific actin nucleation factors such as the Arp2/3 complex, Spire, and formin (Chhabra and Higgs, 2007) . Determining which factors drive actin filament assembly for particular cellular functions is daunting. Formins are evolutionarily conserved proteins that stimulate actin assembly for a variety of processes including division, motility, establishing polarity, stress fiber formation, focal adhesions, and cell-to-cell adhesions (Faix and Grosse, 2006; Goode and Eck, 2007; Higgs, 2005) , which are often deregulated during tumor cell transformation and metastasis (Sahai, 2005) . Not surprising then, formins are involved in malignant tumor function and are highly overexpressed in different cancer cell types including colorectal, carcinoma, leukemia, melanoma, and lymphoid (Favaro et al., 2003; Kitzing et al., 2007; Sarmiento et al., 2008; Zhu et al., 2008) . Determining formin's numerous roles is particularly complicated because most organisms express multiple isoforms (Goode and Eck, 2007) . For example, there are at least 20 formin genes in plants, 18 in mammals, 6 each in Drosophila melanogaster and Caenorhabditis elegans, 3 in fission yeast, and 2 in budding yeast (Higgs, 2005) . A major challenge is to elucidate all formin-dependent cellular functions in both healthy and diseased tissues.
Formins are multidomain proteins that contain a highly conserved actin assembly formin homology 2 FH2 domain and its associated profilin-binding FH1 domain, which are flanked on either side by regulatory domains that coordinate localization and activation (Goode and Eck, 2007; Higgs, 2005) . Some formins are autoinhibited by association of their N-and C-terminal regulatory domains and activated by GTP-bound small RhoGTPases (Goode and Eck, 2007; Wallar and Alberts, 2003) . Upon activation, the FH2 domain either nucleates actin filament assembly or associates with preexisting filaments and remains continuously associated with the elongating actin filament barbed end (Higashida et al., 2004; Kovar and Pollard, 2004) . Processive association allows formins to protect barbed ends from capping proteins (Harris et al., 2004; Kovar et al., 2005; Moseley et al., 2004; Zigmond et al., 2003) and to stimulate the addition of FH1 domain-bound profilin-actin Kovar and Pollard, 2004; Neidt et al., 2008; Paul and Pollard, 2008; Romero et al., 2004; Vavylonis et al., 2006) . As a result, formins produce long-straight filaments that are often bundled in cells and pulled by myosin motors to produce contractile forces, such as the cytokinetic contractile ring and stress fibers (Glotzer, 2005; Naumanen et al., 2008) .
Given that the roles of most formins in different cell types are not known, and the potential for formin as an anti-cancer target, inhibitors of formin-mediated actin assembly would be extremely useful. We report here a simple fluorescence-based in vitro screen and identification of the first general small molecule inhibitor of formin-mediated actin assembly that disrupts formindependent processes from yeast to mammals.
RESULTS AND DISCUSSION

Identification of a Small Molecule that Inhibits Formin-Mediated Actin Assembly
We screened 10,000 commercially available small molecules (ChemBridge) for the ability to prevent mouse formins mDia1(FH1FH2) and mDia2(FH1FH2) from stimulating actin assembly in vitro (see Experimental Procedures). We identified a compound that we named SMIFH2 for small molecule inhibitor of formin FH2 domain-mediated actin assembly (see Figure 1A ). This 2-thiooxodihydropyrimidine-4,6-dione derivative inhibits mouse formin mDia1(FH1FH2)-mediated assembly of profilinactin in a concentration-dependent manner (Figures 2A and 2B) . Half-maximal inhibition occurs at 15.0 mM SMIFH2, and at saturating concentrations of SMIFH2 the rate of assembly is identical to the rate without formin. Control experiments demonstrate that SMIFH2 is specific for formin-mediated actin assembly. High concentrations of SMIFH2 did not eliminate the spontaneous assembly of actin monomers without formin ( Figure 2C ), the addition of actin to the barbed end of preassembled filaments without formin (Figures 2G and 2I ; see Figures S1C and S1E available online), or actin polymerization stimulated with Arp2/3 complex ( Figures 2E and2F) .
With similar potency SMIFH2 also inhibits mDia1(FH1FH2) without profilin, as well as the construct mDia1(FH2) lacking the profilin binding FH1 domain ( Figure 2B ). Thus, the molecular target of SMIFH2 is likely the highly conserved FH2 domain. SMIFH2 also inhibits actin assembly by evolutionarily diverse formin FH1FH2 constructs including C. elegans CYK-1, S. pombe Cdc12, S. pombe Fus1, S. cerevisiae Bni1, and M. musculus mDia2 (Figures 2B and 2C) . Therefore, SMIFH2 is a general inhibitor of actin assembly mediated by formin FH2 domains.
SMIFH2 Inhibits Both Formin-Mediated Nucleation and Elongation
Formins nucleate actin assembly and drive rapid elongation of profilin-actin by remaining continually associated with the elongating barbed end (Kovar, 2006) . We determined that SMIFH2 inhibits formin-mediated nucleation by visualizing the products of spontaneous assembly reactions upon reaching plateau ( Figure 2D ). Filament length is proportional to the number of filaments. Control reactions without formin produce long filaments (21 mm) compared to reactions with formins (1.5 and 0.5 mm for mouse mDia2 and fission yeast Cdc12, respectively). SMIFH2 inhibits formin nucleation, resulting in filament lengths similar to controls without formin (18 and 21 mm for mDia2 and Cdc12, respectively).
We determined that SMIFH2 inhibits formin-mediated elongation by measuring the addition of profilin-actin to preassembled formin-associated filaments ( Figures 2G-2J ). In the absence of SMIFH2, formin-associated filaments rapidly assemble upon addition of profilin-actin. Conversely, SMIFH2 severely blocked the elongation of both Cdc12-and mDia2-associated filaments. Half-maximal inhibition occurs at 4.0 mM SMIFH2 ( Figure 2J ). SMIFH2 did not inhibit the barbed end elongation of filaments without formin (Figures 2G and 2I) .
SMIFH2 Decreases the Affinity of Formin for the Actin Filament Barbed End
We determined that SMIFH2 decreases the affinity of formin for the barbed end by three assays. First, high concentrations of SMIFH2 allow barbed ends to depolymerize in the presence of formin (Figures S1A and S1B). In the absence of SMIFH2, formin significantly inhibits the depolymerization of preassembled filaments upon dilution below the barbed end critical concentration. Concentrations of SMIFH2 above 25 to 50 mM allow rapid barbed end depolymerization in the presence of both Cdc12 and mDia2. Conversely, SMIFH2 had no effect on the barbed end depolymerization rate without formin (Figure S1B) . Second, we determined the effect of SMIFH2 on the ability of formin to bind to the barbed end and reduce the rate of monomer addition ( Figures S1C-S1E ). Cdc12 binds to preassembled barbed ends and severely inhibits their elongation in the absence of profilin (Figures S1D and S1E) (Kovar et al., 2003) . In a concentration-dependent manner, SMIFH2 prevents Cdc12 from binding to the barbed end, allowing filaments to elongate near the control rate ( Figures S1D and S1E ). Conversely, SMIFH2 had no effect on the rate of barbed end elongation in the absence of formin ( Figures S1C and S1E) .
Third, we determined that SMIFH2 does not allow formin to inhibit the end-to-end annealing of actin filaments ( Figure S2 ). Formin-associated filaments do not anneal (Kovar et al., 2003) . SMIFH2 allowed preassembled filaments severed in the presence of Cdc12 to anneal ( Figures S2A and S2B ) and allowed Cdc12-and mDia2-nucleated filament seeds to anneal ( Figures   S2C and S2D ). Conversely, SMIFH2 had no effect on annealing in the absence of formin ( Figures S2A and S2B ).
Direct Observation of Formin Inhibition by Total Internal Reflection Fluorescence (TIRF) Microscopy
To verify that SMIFH2 specifically inhibits formin-mediated actin assembly, we used TIRF microscopy to observe individual filaments assembled from formin in solution (Figure 3) or from formin immobilized on beads (Figure 4 ). When 1.5 mM Mg-ATP actin monomers (33% labeled with Oregon green for visualization) are assembled in the presence of 5.0 nM mDia1(FH1FH2) and 2.5 mM profilin, two filament populations are present that differ by both elongation rate and brightness ( Figure 3A ) . The first population consists of ''bright'' control filaments whose barbed ends are not associated with formin and elongate at 14 subunits/second (sub/s) ( Figures 3A and 3B) . The second population consists of ''dim'' formin-associated filaments that elongate their barbed ends significantly faster at 60 sub/s. 450 s after the reaction was initiated, just over 80% of the filaments were associated with formin ( Figure 3G) .
In reactions containing 100 mM SMIFH2, control filaments were unaffected, whereas the average number of dim forminassociated filaments was significantly reduced to 10% of the total filament population ( Figures 3C-3D and 3G ). The few formin-associated filaments present in reactions containing 100 mM SMIFH2 elongate their barbed ends at the same rate as formin-associated filaments in control reactions without SMIFH2 ( Figure 3D ; 60 sub/s), suggesting that SMIFH2 inhibits forminmediated actin assembly by targeting formin not actin. A plot of the dependence of the percentage of formin-nucleated filaments on the concentration of SMIFH2 revealed half-maximal inhibition at 25 mM SMIFH2 ( Figure 3H ). When 1.5 mM Mg-ATP actin monomers (33% labeled with Oregon green) and 7.5 mM profilin is flowed into a chamber containing 2.0 mm carboxylate beads preabsorbed with GSTmDia1(FH1FH2), actin filaments are nucleated from and remain processively associated with formin immobilized on the beads ( Figure 4A ) (Michelot et al., 2007; Romero et al., 2004) . Each formin-absorbed bead averaged slightly more than four filaments by 375 s ( Figure 4E ), which elongated at a rate of 40 sub/s (Figure 4B) . Filaments processively associated with mDia1 elongate their barbed ends 33% slower in the presence of 7.5 mM profilin than in the presence of 2.5 mM profilin (Figures 3B and 4B) . When incubated with 100 mM SMIFH2 each forminabsorbed bead averaged less than 0.05 filaments (Figures 4C and 4E) , which elongated at 44 sub/s ( Figure 4D ). A plot of the dependence of the average number of filaments per bead on the concentration of SMIFH2 revealed half-maximal inhibition at 15 mM SMIFH2 ( Figure 4F ).
Although formin is likely the molecular target, it is theoretically possible that SMIFH2 binds to actin in a manner that inhibits formin-mediated assembly but not (1) spontaneous actin assembly without formin ( Figure 2C ), (2) barbed end elongation without formin (Figures 2G and 2I and Figures S1C and S1E) , (3) barbed end depolymerization without formin ( Figure S1B ), and (4) Arp2/3 complex-mediated actin assembly (Figures 2E and 2F) . To establish that the molecular target of SMIFH2 is formin, we tested the effect of washing out SMIFH2 from forminassociated beads before the addition of actin monomers (Figures 4G and 4H) . In this case, formin-associated beads, but not actin, are exclusively treated with SMIFH2. We found that extensively washing beads one and five minutes before the addition of actin monomers only partly recovered the nucleation activity of formin-associated beads to 0.5 and 1.25 filaments per bead ( Figure 4G ). Increased nucleation activity after five minutes likely reflects the dissociation rate of SMIFH2 from formin.
Inhibition of the Fission Yeast Formin-Dependent Actin Cytoskeleton
We examined the effect of SMIFH2 on fission yeast to determine whether the compound inhibits formin-mediated processes in cells. Fission yeast assembles four distinct filamentous actin structures that depend on different actin nucleation factors ( Figure 5A ) (La Carbona et al., 2006; Marks and Hyams, 1985) . The Arp2/3 complex is required for endocytic actin patches at sites of polarized growth McCollum et al., 1996) . Three formin isoforms are specifically required for polarized actin cables (For3p; Feierbach and Chang, 2001; Nakano et al., 2002) , the cytokinetic contractile ring (Cdc12p; Chang et al., 1997) , and the mating projection tip (Fus1p; Petersen et al., 1998) . We imaged fission yeast cells expressing GFP-CHD (actin binding domain of Rng2) to label the entire filamentous actin cytoskeleton ( Figure 5A ) (Martin and Chang, 2006) . An asynchronous population of control cells treated with DMSO contained Arp2/3 complex-dependent patches as well as formin-dependent actin cables and contractile rings. The non-specific actin depolymerizing drug LatA completely disassembled all filamentous actin structures ( Figure 5A ). The Arp2/3 complex inhibitor CK-666 specifically disassembled Arp2/3 complex-dependent actin patches ( Figure 5A ) (Nolen et al., 2009 ). In contrast, 25 mM SMIFH2 disassembled formindependent actin cables and contractile rings, but not actin patches ( Figure 5A ). The concentration of SMIFH2 required to disassemble actin cables and contractile rings varied ( Figure 5B ). Whereas actin cables were lost in the presence of only 2.5 mM SMIFH2, disassembly of contractile rings required 25 mM SMIFH2. It is possible that contractile rings are more robust than actin cables or that For3 is more sensitive to SMIFH2 than is Cdc12.
To quantify the inhibitory effect of SMIFH2 on formindependent actin cables and contractile rings, we imaged fission yeast cells expressing integrated GFP fusions to proteins that localize to particular actin structures ( Figure 5C ). As expected, actin capping protein-labeled actin patches (Acp2-GFP) were observable in 100% of cells treated with 10 mM SMIFH2. However, the localization of GFP-tagged proteins to formindependent actin cables and the contractile ring was abrogated. Although type V myosin (Myo52-GFP) normally localizes to the tips of interphase cells via actin cables, 10 mM SMIFH2 caused Myo52-GFP to become distributed throughout the cell. Myo52-GFP also distributes throughout the cell in formin For3 null cells that completely lack actin cables (Feierbach and Chang, 2001) . Additionally, both the regulatory light chain (Rlc1-GFP) and type II myosin (Myo2-GFP) appeared as punctate spots rather than continuous smooth formin-dependent contractile rings at the division site in 10 mM SMIFH2-treated cells.
Structure-Activity Relationship of SMIFH2
To gain insight into the structure-function profile of SMIFH2 (1), we characterized the ability of six other compounds (2-7), including both pyrimidine-2,4,6-triones and 2-thiooxodihydropyrimidine-4,6-diones, to inhibit formin-mediated actin assembly in vitro and disrupt the fission yeast actin cytoskeleton (Figure 1) . We found that the ability of analogs to inhibit forminmediated actin assembly in vitro ( Figures 1B and 3E-3G ) correlated closely with their ability to disrupt the fission yeast formindependent actin cytoskeleton ( Figure 1C) . None of the analogs removed Arp2/3 complex-dependent actin patches. Analogs 2 and 3 were the most potent both in vitro and in fission yeast. Similar to SMIFH2 (1), cells treated with 10 mM of analogs 2 and 3 for 30 min lost actin cables, resulting in mislocalization of the type V myosin Myo52-GFP from cell tips and throughout the cell. Analog 4 had lower potency, whereas analogs 5, 6, and 7 had little effect on both formin-mediated actin assembly in vitro and actin cables in fission yeast cells. Our results strongly suggested that the thiourea moiety of SMIFH2 is an important pharmacophoric element of this compound since a substitution of this unit by the urea fragment resulted in substantial loss in activity. A series of structurally related pyrimidine-2,4,6-triones has been previously reported to inhibit cell migration by modulating the activity of mucosal addressin cell adhesion molecule-1, with compounds 5 and 6 being the most potent in the series (Harriman et al., 2008) . Despite notable structural homology between 5, 6, and SMIFH2 (1), there is a substantial difference in their ability to inhibit formin-mediated actin assembly. This data suggests that the cell-based activity of SMIFH2 is due to selective modulation of formin and that the activity profile is uniquely linked to the thiourea-containing structure of this compound.
SMIFH2-Induced Cytotoxicity and Growth Inhibition of NIH 3T3 Fibroblasts
NIH 3T3 fibroblasts were incubated with a range of concentrations of SMIFH2 to determine its effects on adherent mammalian cells. Cell viability was assessed after 24 hr. SMIFH2 elicited cytotoxicity with an IC 50 of 28 mM ( Figure 6A ). We also observed dose-dependent growth inhibition of NIH 3T3 fibroblasts within a period of 96 hr ( Figure 6B ). In addition, cells cultured in SMIFH2 with concentrations as low as 2.5 mM were observed to have cytokinesis defects, as measured by the percentage of multinucleated cells. After 4 days, 8.6 ± 2% of cells cultured in 2.5 mM SMIFH2 had multiple nuclei as compared to 1.1 ± 0.7% of cells treated with a DMSO control. This cytokinesis defect is consistent with recent data showing that siRNA depletion of mDia2 in NIH 3T3 fibroblasts increases the percentage of binucleate cells to 35% (Watanabe et al., 2008) .
Cellular Morphology and Protrusion Phenotypes Observed in NIH 3T3 Fibroblasts
We took time-lapse images of NIH 3T3 fibroblasts to visualize SMIFH2-induced phenotypes in mammalian cells. The migration rate of cells treated with 10 mM SMIFH2 for >2 hr was reduced two-fold compared to control cells ( Figure 6C ), which is consistent with previous studies implicating mDia2 in cell migration (Gupton et al., 2007) . Control cells are characterized by a spread morphology and thin sheet-like protrusions termed lamellipodia that require Arp2/3 complex-mediated actin assembly. Over 90% of control cells have lamellipodia ( Figures 6D and 6E) . Despite a less spread morphology, approximately 20% of cells treated with less than 20 mM SMIFH2 for 6 hr still extended lamellipodial protrusions ( Figures 6D and 6E ). Mouse formin mDia2 has been implicated in the assembly of cortical actin required for maintaining plasma membrane integrity, and inhibition of mDia2 led to abundant nonapoptotic membrane blebbing . Consistent with this result, we observed that 20% of cells treated with 10-20 mM SMIFH2 for 6 hr exhibit constitutive, dynamic, small (<1 mm) blebs ( Figures 6D and 6E) . At 30 mM SMIFH2, nearly all the cells exhibited large blebs ( Figures 6D and 6E) , which is consistent with an IC 50 of 28 mM SMIFH2 for NIH 3T3 fibroblasts ( Figure 6A ). Effects of SMIFH2 perfusion were reversible on the time scale of 5 to 10 min (data not shown).
The observed phenotype changes slowly over time when cells are incubated with 10 mM SMIFH2 ( Figure 6F ). After 2 hr 60% still retain the lamellipodial protrusive phenotype, whereas 40% protrude by means of small dynamic blebs ( Figure 6F ). After 7 hr the percentage of cells exhibiting either lamellipodial protrusions or constitutive small blebbing decreases dramatically, while the percentage of cells that lack protrusive activity and appear phase dark near the cell periphery increases ( Figure 6F) . Because of the static, round shape of these cells, we term this phenotype ''bulbous'' ( Figure 6D ). The phase dark appearance near the cell periphery suggests an increase in cell thickness in this region, which may be due to decreased stability of the filamentous actin cortex. Numbers in the top left corner indicate the percentage of cells containing Arp2/3 complex-dependent actin capping protein patches (Acp2-GFP), type V myosin localized to the cell tip via formindependent actin cables (Myo52-GFP) (Win et al., 2001) , or normal (not punctate) localization of regulatory light chain (Rlc1-GFP) and type II myosin (Myo2-GFP) to the formin-dependent contractile ring.
F-Actin Cytoskeleton in SMIFH2-Treated 3T3 Fibroblasts
We imaged filamentous actin and the focal adhesion marker paxillin to assess the organization of the actin cytoskeleton in cells treated with SMIFH2 ( Figure 7A ). In fibroblasts the actin cytoskeleton is typically organized into prominent type II myosin-dependent contractile bundles. The width and actin filament density of these bundles were characterized by quantifying the variation in intensity of fluorescent phalloidin across the bundles. ''Thick'' F-actin bundles have a mean width of 1.5 mm and a 2.4-fold higher local actin filament density compared with the surrounding region ( Figures 7A and 7B ). ''Thin'' F-actin bundles have a mean width of 0.7 mm and a 1.5-fold enhanced actin filament density. Interestingly, focal adhesions are similar in cells with thick or thin F-actin bundles ( Figures 7A) . In control cells, over 80% of the fibroblasts exhibited predominately thick F-actin bundles, with only 20% exhibiting thin bundles (Figure 7C) . However, 60% of cells incubated with 10 mM of SMIFH2 for 2 hr have thin F-actin bundles and only 20% have thick F-actin bundles ( Figure 7C ). Moreover, approximately 5% of the spread cells have a disorganized lamellar network and no F-actin bundles ( Figures 7A and 7C ). In cells lacking F-actin bundles, focal adhesion plaques were significantly reduced in size, reminiscent of nascent focal complexes that are observed to form in the absence of myosin II-driven tension ( Figure 7A ) (Choi et al., 2008) . As the concentration of SMIFH2 was increased to 20 mM, the percentage of cells that lacked F-actin bundles increases to 50%, with the rest of the population showing only thin bundles ( Figure 7C ). Importantly, all spread cells have an F-actin-rich lamellipodia near the cell periphery, which is dependent on Arp2/3 complex-mediated actin assembly ( Figure 7A , arrows). Thus, at intermediate SMIFH2 concentrations the filamentous actin organization of cells that remain spread is in the form of thin F-actin bundles or an isotropic lamellar meshwork. This is consistent with previous reports that mDia1, in addition to the Rho effector Rho kinase, is essential to building contractile stress fibers and the growth of focal complexes (Hotulainen and Lappalainen, 2006; Riveline et al., 2001; Watanabe et al., 1999) . Changes in F-actin organization and adhesion were not observed with analog compounds (data not shown).
Impact of SMIFH2 on a Carcinoma Cell Line A549
We treated the carcinoma cell line A549 with a range of SMIFH2 concentrations to determine the effect of SMIFH2 on diverse cells. A549 cells are exceptionally more tolerant, with an IC 50 near 75 mM SMFH2 and a higher dose of SMIFH2 was required to inhibit growth ( Figures S3A and S3B) . Treatment of A549 cells for 4 days with 30 mM SMIFH2 increases the percentage
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Phenotype at 6 hr incubation Phenotype in 10 µM SMIFH2 of multi-nucleated cells 4-fold, suggesting a SMIFH2-induced cytokinesis defect. In contrast to the NIH 3T3 fibroblasts, a majority of A549 cells treated with 30 mM SMIFH2 remained spread over the course of an 8 hr time-lapse movie. However, 40% have spherical bleblike protrusions that rapidly extended and retracted at the cell periphery ( Figures S3C and S3D ). In 10% of cells, these protrusions were stabilized by adhesion to the external matrix and resulted in changes in cell shape ( Figures S3C and S3D ). Immunofluorescence images revealed regions near the cell periphery with high filamentous actin intensity and numerous small focal complexes that existed beyond the zone of large focal adhesions ( Figure S3E ). Thus, it appears that SMIFH2 treatment induces bleb-like protrusions near the cell periphery without significantly altering the formation of focal complexes. This is consistent with reports suggesting that the RhoA pathway and its effector, mDia1, are instrumental in maintaining cortical integrity to limit protrusive activity (Worthylake and Burridge, 2003) . Such bleb-like protrusions have been observed in several cell types, but the relative contributions of actin polymerization and local cortical tension in regulating cellular protrusions has not been well established (Fackler and Grosse, 2008) . These results suggest that reduction in formin-mediated actin polymerization at the plasma membrane results in local cortical weakening. In this scenario, the forces for protrusion might originate from osmotic pressure-driven changes in membrane shape rather than from actin polymerization.
Additional work is required to elucidate the mechanism of differences in drug toxicity between these two cell lines; possible reasons are changes in expression of different isoforms of formins or different formin activity due to different levels of the formin activator RhoA. 
Future Considerations
Analysis of SMIFH2 and the Arp2/3 complex inhibitor CK-666 demonstrates the usefulness of fission yeast to determine the specificity of drugs on actin cytoskeleton processes. Extensive work is required to determine which specific actin-modulating proteins are required for the at least 15 processes in vertebrates (Chhabra and Higgs, 2007) . Fission yeast assembles actin into just four structures (La Carbona et al., 2006; Marks and Hyams, 1985) . The ease of genetic manipulation and visualization of functional GFP-tagged proteins expressed from their endogenous locus has provided a nearly complete profile of which evolutionarily conserved actin-binding proteins are required for each structure in budding and fission yeast (La Carbona et al., 2006; Moseley and Goode, 2006) . Inhibitor specificity can be investigated in yeast, and then used to determine which processes in animals depend on the drug's target. Yeast has also been useful for testing the specificity of drugs targeting other fundamental cellular processes (Lehar et al., 2008; Lopez et al., 2008) .
As a general inhibitor, which targets diverse formin isoforms with similar potency, SMIFH2 may be a useful drug for identifying cellular processes dependent on formin-mediated actin assembly in a broad range of experimental systems. However, it will be important to isolate formin isoform-specific inhibitors to determine which formin is required for a particular cellular process. Furthermore, particular formin isoforms are involved in malignant tumor formation and are highly overexpressed in a range of cancer cell types (Favaro et al., 2003; Kitzing et al., 2007; Sarmiento et al., 2008; Zhu et al., 2008) . Isoform-specific inhibitors are likely to be better anti-metastatic tumor drugs because they may target tumor cells while having less impact on surrounding healthy tissues.
SIGNIFICANCE
Formins are required to stimulate actin filament assembly at the correct time and place to drive fundamental cellular processes such as division, adhesion, and establishing polarity. Formin inhibitors would be an extremely useful reagent because most eukaryotic organisms express multiple formins whose cellular roles have not been determined and because formins are required for processes deregulated during metastic tumor formation.
We established a simple fluorescent-based in vitro screen to discover for the first time a general small molecular formin inhibitor that we named SMIFH2 (small molecule inhibitor of formin FH2 domains). SMIFH2 is a general formin inhibitor that targets evolutionarily diverse formin isoforms from budding yeast, fission yeast, nematode worm, and mouse, with similar 5 to 15 mM half-maximal potency. SMIFH2 inhibits formin at multiple points from preventing both nucleation and processive barbed end elongation and decreases formin's affinity for the barbed end. We verified that SMIFH2 abolishes formin-dependent actin cytoskeletal structures in both fission yeast and animal cells. SMIFH2 disrupts formin-dependent actin cables and contractile rings in fission yeast, but does not target endocytic actin patches, which are dependent on the other major actin nucleation factor, Arp2/3 complex. Although it is possible that SMIFH2 has additional cellular targets, the potency of analog compounds on formin-mediated actin assembly in vitro directly correlates with their potency on the fission yeast formin actin cytoskeleton. In animal cells, SMIFH2 severely disrupts formin-dependent stress fibers and perturbs cell division and motility, but does not disrupt Arp2/3 complex-dependent lamellipodia near the cell periphery.
SMIFH2 may be a useful drug to elucidate formindependent processes in a wide range of organisms and cell types. Future work will focus on elucidating where SMIFH2 binds formin, optimization of SMIFH2 activity, and expansion of the in vitro screen to identify formin isoform-specific inhibitors.
EXPERIMENTAL PROCEDURES Compounds and Protein Purification
Compounds were purchased from ChemBridge Corporation: SMIFH2, analog 2, analog 3, analog 4, analog 5, analog 6, and analog 7. Procedures for protein purification can be found in the Supplemental Experimental Procedures.
Formin Inhibitor Screen
Small molecules were initially screened by a single-point pyrene-fluorescence assay. In 96 well plates, 1.5 mM Mg-ATP-actin (20% pyrene-labeled) and either 10 nM mDia1(FH1FH2) or 20 nM mDia2(FH1FH2) with 1.5 mM mouse profilin MmPRF1 was assembled in the presence of 960 pools of 8 small molecules (Chembridge; 12.5 mM final concentration of each small molecule) for 30 min and read on a Safire 2 fluorescent plate reader (Tecan). Positive hits had 50% or lower fluorescence than control reactions without small molecules. Sixtyone positive pools were re-screened kinetically by following the time course of pyrene fluorescence (actin assembly) of 1.5 mM Mg-ATP-actin with 10 nM mDia1(FH1FH2) or 20 nM mDia1(FH1FH2) and 1.5 mM MmPRF1. Forty-six positive pools assembled at least 2-fold slower than control reactions without small molecules. The 368 individual compounds were subsequently screened against both mDia1 and mDia2 by the single-point assay (42 compounds inhibited pyrene fluorescence by at least 50%) and by the kinetic assay (34 compounds slowed the rate of assembly by at least 2-fold). Thirty of the thirty-four compounds did not inhibit the rate of 1.5 mM actin assembly in the absence of formin. The final 30 compounds were screened kinetically over a range of concentrations. Two small molecules, SMIFH2 and analog 2, inhibited formin-mediated actin assembly by at least 50% at a concentration of 10 mM and were characterized further.
Actin Biochemistry
Procedures for fluorescence spectroscopy, microscopy of fluorescently labeled actin filaments, and TIRF microscopy can be found in the Supplemental Experimental Procedures.
Fission Yeast
Fission yeast strains and microscopy procedures can be found in the Supplemental Experimental Procedures.
Tissue Culture NIH 3T3 Fibroblasts (ATCC) were cultured in high-glucose DMEM (CellGro), supplemented with 10% FBS (Hyclone), L-glutamine (GIBCO), and Penicillin/ Streptomycin (GIBCO). A549 carcinomic human alveolar basal epithelial cells were cultured in F12K medium (ATCC), supplemented with 10% FBS (ATCC) and Penicillin-streptomycin-glutamine solution (ATCC).
Cell Viability
All assays were performed using at least three replicate wells for each compound concentration tested. Serial dilutions (2-or 3-fold) in DMSO were performed using a stock solution of SMIFH2 in DMSO. We seeded cells in 96-well white plates at the density of 1000 cells/well (A549 cell line) or 2000 cells/well (3T3 cell line) in 100 ml of the appropriate cell culture media. The cells were allowed to attach and grow for 24 hr before treatment with serially diluted SMIFH2 solutions pre-diluted in 25 ml growth media for each data point. After indicated incubation periods, cell viability was determined with an ATPlite 1step luminescence assay kit (PerkinElmer) according to the manufacturer's instructions. Luminescence was analyzed using a Wallac Victor 3 plate reader (PerkinElmer).
Immunofluorescence NIH 3T3 Fibroblasts and A549 carcinomic human alveolar basal epithelial cells were plated onto glass coverslips and allowed to spread for 24 hr. Cells were fixed at room temperature for 15 min in 4% paraformaldehyde, 0.5% Triton X-100, and 1.5% bovine serum albumin as a blocking agent. Paxillin antibody (1:400; Santa Cruz Biotechnology) and Alex Fluor 488 phalloidin (1:400; Molecular Probes) were diluted in 1.5% BSA in phosphate buffered saline (PBS) and incubated for 1 hr at room temperature. After three washes in PBS, coverslips were incubated overnight at 4 C in Alexa 568-conjugated anti-rabbit (1:400; Molecular Probes) and were subsequently washed three times in PBS and mounted in Prolong Gold Antifade reagent (Molecular Probes). Images were acquired with an inverted Nikon Ti microscope equipped with a cooled CCD camera (Photometrics, Coolsnap HQ2).
Time-Lapse Imaging NIH 3T3 Fibroblasts or A549 carcinomic human alveolar basal epithelial cells were plated onto glass coverslips and allowed to spread for 24 hr. Coverslips were placed in a sealed chamber with the designated quantity of drug and 20 mM HEPES. Images were collected with a CCD Photometric CoolSnap HQ Camera at 5 min intervals over 8-12 hr with a 203 lens on an automated (Metamorph 7.5.4.0; Universal Imaging Corporation) microscope (Nikon Eclipse Ti) with a heated and motorized stage. For each experiment, ten individual cell fields were recorded. Phenotypic frequency was measured by scoring incidence of occurrence at each indicated time point. Cells that did not spread or left the field of view during the length of the experiment were not scored.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, three figures, and seven movies and can be found with this article online at http:// www.cell.com/chemistry-biology/supplemental/S1074-5521(09)00333-0.
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